Metoo Line™ PDO MONO Thread
29G 38mm Absorbable Monofilament
Metoo Line™ PDO MONO Threads are 100% polydioxanone monofilaments with 98.7% biocompatibility. Clinically shown to increase collagen production by 35% while maintaining tensile strength for 180-210 days. Ideal for non-surgical facial contouring with 24-48 hour downtime. Complete absorption occurs within 6-8 months with minimal tissue reaction.
- Bioabsorbable: Complete absorption within 6-8 months with minimal tissue reaction
- Precision Design: 29G cannula ensures minimal trauma during insertion
- Multi-Area Application: Effective for face, neck, décolletage, and body contouring
- Rapid Recovery: 24-48 hour downtime with proper aftercare management
Polydioxanone (PDO) Monofilament
Blunt cannula
Gamma-irradiated
Multiple threads per sealed box
Controlled room temperature in original packaging
Licensed Practitioners Only: Strictly for use by MD, DO, NP, PA with documented thread lift training
Anatomy Knowledge: Requires thorough understanding of facial anatomy and complication management
Technique Matters: Results vary significantly based on individual patient factors and practitioner technique
Contraindications: Not recommended for patients with certain skin conditions or unrealistic expectations
• Metoo Line PDO Threads require prescription and professional administration
• Always follow aseptic techniques during procedure
• Monitor for adverse reactions during and after procedure
• Provide proper aftercare instructions to patients
• Manufacturer not liable for improper storage or usage errors
We are an authorized wholesale distributor of medical products. This product information is provided for professional healthcare providers only. We do not sell directly to end-users. All products must be prescribed and administered by qualified medical professionals in accordance with local regulations. Product specifications may vary – please confirm actual parameters before ordering. Product images may differ from actual packaging.
Reviews
There are no reviews yet.